BTIG Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $1
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $8 to $1.
BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $8 to $1.